Top educators in dermatology will come together to deliver CME lectures and engaging panel discussions via a premiere virtual platform during the 

 Virtual Dermatology CME Conference in September.

The virtual experience has been designed to connect attendees with experts who will provide insights into the latest in diagnostic and therapeutic strategies through master's classes, core competency workshops, and Q&A lectures.  

Topics will span basic education on skin structure and function to the latest literature-based findings and updates across subspecialty areas, including infectious disease, hair disorders,  acne and rosacea, psoriasis, pigmentation disorders, and more.

Learn more about MauiDerm Connect and register 

Articles

Maui Derm

Top educators in dermatology will come together to deliver CME lectures and engaging panel discussions via a premiere virtual platform. Learn more about MauiDerm Connect coming September  23-27.

MauiDerm Connect will live stream in September

 for patients experiencing loss of bone and deep soft tissue.

In part three of our discussion with Dr. Sundaram, she explains how botulinum toxin can be used to address erythema and flushing caused by rosacea, as well as other considerations providers will want to keep in mind when using this treatment in their patients.

More from Dr. Sundaram’s presentation at the AAD Virtual Meeting Experience (VMX): 

Questions? Contact Dr. Sundaram by messaging her through Instagram at 


Sundaram H. What's new in aesthetic therapeutics. Therapeutic Hotline Session. AAD VMX 2020; June 12, 2020.

Videos

American Academy of Dermatology 

Botulinum toxin may help address erythema and flushing in patients with refractory rosacea, according to data presented by Hema Sundaram, MA, MD, FAAD, at the AAD Virtual Meeting Experience (VMX) on June 12.

Can botulinum toxin benefit rosacea patients?

The BE VIVID and BE READY studies of bimekizumab in psoriasis show strong, long-lasting patient responses and no unexpected safety signals.

Tapinarof cream demonstrates positive phase 2b results

“Dermatologists and patients with psoriasis are looking for a treatment that delivers speed, depth and durability,” says Kenneth Gordon, M.D., professor and chair of dermatology at the Medical College of Wisconsin and principal BE READY investigator.

The phase 3 data demonstrate bimekizumab’s strong potential to deliver in these areas, adds principal BE VIVID investigator Kristian Reich, M.D., Ph.D. He is professor for translational research in inflammatory skin diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Germany.

Bimekizumab is a second-generation IL-17 inhibitor, says Dr. Reich. 

 and secukinumab block IL-17A, and brodalumab inhibits the IL-17A receptor.

“We believe IL-17A and F are the main drivers of the psoriatic disease process,” he notes.

Dr. Gordon adds that the IL-17F protein is considerably more present in psoriatic plaques than IL-17A.

“So while IL-17A might have a little more physiological activity, both of these molecules are considered significant for the treatment of psoriasis,” he says.

Phase 3 results show apremilast safe, effective for plaque psoriasis

“Theoretically, if you block F in addition to A, hopefully you should see even higher levels of response,” notes Dr. Reich.

Indeed, the 567-patient BE VIVID trial produced some of the highest response levels ever recorded. At week 16, the proportions of patients randomized to bimekizumab who achieved Psoriasis Area and Severity Index (PASI) 90 and 100 were 85% and 58.6%, respectively. The corresponding figures for ustekinumab were 49.7% and 20.9%. Also at week 16, 84.1% and 53.4% of patients on bimekizumab and ustekinumab reached investigator global assessment (IGA) scores of zero or one with at least a two-point improvement over baseline.

Additionally, 76.9% of bimekizumab-treated patients reached PASI 75 by week four, versus 15.3% of ustekinumab-treated patients. At week 52, an approximately 25-point difference in PASI 90 and 100 rates between bimekizumab and ustekinumab persisted.

The BE VIVID study spotlights bimekizumab’s speed and durability of response, says Dr. Reich.

“There is no longer a trade-off when it comes to onset and maintenance of response with this IL-17 inhibitor,” he adds. “You’re getting the best of both worlds by blocking IL-17F in addition to A.”

In BE READY, investigators randomized 435 patients with moderate-to-severe-psoriasis to bimekizumab every four weeks or placebo. At week 16, investigators rerandomized PASI 90 responders to bimekizumab every eight weeks, every four weeks or placebo through week 56.

Oral apremilast effectively treats scalp psoriasis

Week 16 PASI 90, PASI 100 and IGA 0/1 rates among bimekizumab-treated patients were 90.8%, 68.2% and 92.6%, respectively, versus 1.2% in all three metrics for placebo. More impressive, says Dr. Gordon, are week four PASI 75, 90 and 100 rates of76%, 45% and 19%.

Week 56 PASI 90 rates for four- and eight-week dosing were 86.8% and 91%, respectively; the corresponding figures for IGA 0/1 were 86.8% and 90%. Conversely, 16.2% of patients rerandomized to placebo maintained PASI 90 by week 56.

“But this is not a rapid return of disease with bimekizumab therapy,” says Dr. Gordon. Median time to relapse (defined as PASI 75) was 28 weeks.

In both studies, bimekizumab was well tolerated. The most common bimekizumab-related adverse events included nasopharyngitis and oral candidiasis, the latter of which was generally mild-to-moderate and an expected effect of IL-17 inhibitors. No BE READY patients stopped therapy due to candidiasis, while five did so in BE VIVID.

Dr. Gordon says, “Data from both BE READY and BE VIVID suggest that bimekizumab may allow patients to have a very high likelihood of robust responses in their psoriasis and even clearance of their disease. This happens quickly and can be maintained effectively while having very good tolerability.”

Kristian Reich,MD, PhD, Kim A Papp MD, Andrew Blauvelt MD, et al. “Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE VIVID: a 52-week phase 3, randomized, double-blinded, ustekinumab- and placebo-controlled study,” American Academy of Dermatology VMX. June 13, 2020.

Kenneth Gordon MD, Peter Foley MD, James Kruger MD, et al. “Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE READY, a 56-week phase 3, randomized, double-blinded, placebo-controlled study with randomized withdrawal,” American Academy of Dermatology VMX. June 13, 2020.

Dr. Reich has served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Avillion, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Covagen, Dermira, Eli Lilly, Forward Pharma, Fresenius Medical Care, Galapagos, GSK, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Medac, Merck Sharp & Dohme, Miltenyi Biotec, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB Pharma, Valeant and XenoPort.

Dr. Gordon has received honoraria and/or research support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermira, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma and UCB Pharma.

Phase 3 data announced at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020 demonstrate that the second-generation IL-17 inhibitor may offer long-lasting, safe treatment for patients with psoriasis.

Bimekizumab phase 3 data reflect rapid, durable response

High-dose red light photodynamic therapy (PDT) offers highly effective and durable treatment for acne by selectively destroying the sebaceous gland. However, a search for alternative light-based strategies has continued because high-dose PDT causes significant side effects.

RELATED: Dr. Baldwin discusses pipeline treatments that are showing promise for acne patients

Speaking about device-based acne treatments at Maui Derm for Dermatologists 2020 meeting, Fernanda Sakamoto, Ph.D., M.D., discussed PDT and other approaches for targeting the sebaceous gland.


	Discussing high-dose PDT, Dr. Sakamoto says that when the treatment is performed using 20% aminolevulinic acid (ALA) with a three-hour incubation period followed by high fluence red light exposure, PDT is one of the most efficacious treatments available for acne. Severe acne can be cleared in 80% to 90% of patients, and significant acne improvement can persist for longer than six months.

“In fact, in my clinical practice, acne remission following high-dose PDT can last longer than after isotretinoin treatment. In addition, results of a recently published trial comparing ALA 20% with red light PDT versus adapalene gel 0.1% plus oral doxycycline for patients with moderate inflammatory acne showed that the PDT approach was more effective than what we usually do,” says Dr. Sakamoto, assistant professor of dermatology, Harvard Medical School, Boston, Mass.

Nevertheless, high-dose PDT is not widely used because of its side effects that can be very difficult for patients to tolerate. The procedure causes significant pain during treatment, a sunburn-like reaction, and intense blistering and oozing.

“Some clinicians also report difficulty with billing. Therefore, economics may be another factor in the underutilization of PDT for acne,” Dr, Sakamoto says.


	Historically, there is no evidence that lasers are more effective for treating acne than conventional therapies. Dr. Sakamoto proposes that failure to target the correct chromophore limited the potential for achieving better results with laser therapy.

RELATED: Dr. Gold offers more insight on energy-based devices for acne

“Because acne is an inflammatory disease of the pilosebaceous unit, optimization of selective photothermolysis could be achieved by targeting lipids in the sebaceous glands rather than water, melanin and blood that are the targets of lasers that have been tried to treat acne,” she says.

To develop selective photothermolysis using non-selective wavelengths as a treatment for acne, Dr. Sakamoto, R Rox Anderson, M.D., and colleagues at the Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Mass., implemented the use of micro gold shells that can penetrate the sebaceous gland and serve as a laser light-absorbing chromophore. The shells have a silica core that is covered in gold. Changing the thickness of the gold layer on the shells allows wavelength tuning, Dr. Sakamoto explains. 

Initial work using the micro gold shells for acne treatment was done with a near infrared 810-nm hair removal laser. A 1064-nm laser offers deeper penetration and has the additional advantage of not being absorbed by melanin.

Sebacia has received FDA 510(k) clearance for the use of its gold microparticles (Sebacia) as an accessory to 1064 nm lasers to facilitate photothermal heating of sebaceous glands for the treatment of mild-to-moderate inflammatory acne. The company plans to limit initial commercial availability to California and Washington, DC. Clinical trial results showed that inflammatory lesion count was reduced by a mean of 85% from baseline. In addition, 56% of patients became medication-free after the treatment and 86% were able to avoid use of systemic medications, Dr. Sakamoto reports.

Another strategy is focusing on the development of a laser that will directly target sebum. Using the free electron laser at the Jefferson National Accelerator in Newport News, Va., Dr. Sakamoto in collaboration with Dr. Anderson determined that sebum had an absorption peak at around 1720-nm. They also found using that wavelength that laser-induced heating of sebaceous glands was approximately 1.5-fold higher than heating of water.

Dr. Sakamoto says further work and advances in fiber laser technology led to the development of a user-friendly 1726-nm laser that is now being investigated in a clinical trial.

RELATED: Adjunct therapies may support fractional CO

The treatment is performed using a multiple dose strategy that aims to preferentially heat and destroy the sebaceous glands without causing damage to the epidermis and dermis. Preliminary data from the clinical trial are promising.

“We have been asked what happens when sebaceous gland activity is turned off. We know that babies have non-active sebaceous glands, and so the answer to that question is that you end up with baby-like skin,” Dr. Sakamoto says. “Destroying the sebaceous glands as a treatment for acne may be a good idea.”

Dr. Sakamoto is a consultant to Sebacia and to Acure Laser. Both companies have licensed patents from Dr. Sakamoto’s employer, Massachusetts General Hospital, Boston, Mass.

Sebaceous gland destruction a viable strategy to treat acne

George Martin, M.D., dermatologist and program director for the Maui Derm meetings, has been working with the Maui Derm faculty, immunologists and members of industry to share emerging data regarding the novel coronavirus with the dermatology community.

To learn more about the data discussed in this video, 

George Martin, M.D., dermatologist and program director for the Maui Derm meetings, has been working with the Maui Derm faculty, immunologists and members of industry to share emerging data regarding the novel coronavirus with the dermatology community. Listen to his insights in this video.

Maui Derm sheds light on emerging COVID-19 data

The American Academy of Dermatology (AAD), Lupus Foundation of America, American College of Rheumatology, and Arthritis Foundation, 

sent a letter to the White House Coronavirus Task Force

 March 24, outlining concerns about a growing shortage of medications required for managing patients with lupus and rheumatoid arthritis.

After President Donald Trump said in a March 19 press conference that an anti-malaria drug could treat the coronavirus disease COVID-19, 

Hydroxychloroquine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus and rheumatoid arthritis, and tens of thousands of Americans depend on the medication to manage symptoms.

“For patients with lupus, hydroxychloroquine is the only medication shown to increase survival,” the letter reads. “[It] is the cornerstone of therapy, used in most patients.”

Following a series of small studies indicating the drug’s potential benefit for the treatment of COVID-19, hospitals began purchasing large quantities, 

 and manufacturers are reporting back orders.

“Patients are indicating that they are not able to fill their prescriptions and are concerned about continued access to their treatment. We are encouraged that manufacturers - who are currently manufacturing or authorized to manufacture hydroxychloroquine - will be increasing supply to not only meet the needs of patients with COVID-19 but also patients with lupus and rheumatoid arthritis,” Bruce Harris Thiers, M.D., FAAD, president of the American Academy of Dermatology tells 

Patients with these conditions need this drug to effectively manage their health conditions. If patients can’t fill their prescriptions, they could face flares that significantly impact quality of life, says Alison Ehrlich, M.D., MHS, a dermatologist in Washington, D.C.

The organizations have requested the White House Task Force to work with the pharmaceutical industry, pharmacies and the FDA to 

 that are aimed at mitigating the effects of the shortage, including increasing monitoring and timely reporting of shortages; utilizing existing authorities to increase the production and supply of the drugs; and taking action to ensure current supplies are allocated for patients taking them for indicated uses.

 as a treatment to reduce the duration of symptoms and viral shedding in patients with mild-to-moderate COVID-19. However, recent 

 of 30 patients, reported March 24, by Bloomberg News, showed that hydroxychloroquine was no more effective than managing patient symptoms conventionally.

The study, which was conducted by researchers from the department of infection and immunity at the Shanghai Public Health Clinical Center, involved 15 patients treated with hydroxychloroquine and 15 controls who were managed with bed rest, oxygen inhalation, anti-viral drugs recommended in China’s treatment guidelines, and antibiotics when necessary. Of the 15 patients treated, 13 tested negative after one week of treatment vs. 14 patients in the control group who were managed conventionally. One patient in the treatment group progressed to severe disease and four patients developed diarrhea and signs of possible liver damage. The researchers concluded that a larger-scale investigation is required to better understand the drug’s benefit and risk profile.

“Our scientific clinical trials data is not as robust as the media attention,” Dr. Ehrlich says. “We are already seeing some of the dangers of unsupervised use as witnessed in toxicity cases in Nigeria (3 patients) and Arizona (2 patients).”

She says, that while chloroquine and its less toxic derivative, hydroxychloroquine, are generally safe when dosed correctly, the clinical trials data is still limited for this indication. The studies that have supported recommendations for the drug’s use in the treatment of the current pandemic are not high-quality well controlled studies.

While there are no drugs approved to treat, cure or prevent COVID-19, at this time, there are several potential treatments that may help ease the symptoms from a supportive care perspective, 

. The FDA says it is working closely with the scientific community around the world and several clinical trials are underway.

According to Dr. Ehrlich, several other drugs being studied are interesting. For example, “IL-6 blocking agents may have a role in decreasing pulmonary inflammation,” she says. Interleukin-6 (IL-6) may play a role in driving the overactive inflammatory response in the lungs of patients who are critically ill with COVID-19.

Regeneron and Sanofi have initiated a phase 2/3 clinical trial evaluating the IL-6 inhibitor sarilumab (Kevzara) in patients with severe COVID-19.  Regeneron Pharmaceuticals also

in developing a multi-antibody cocktail for prophylaxis exposure to COVID-19, as well as treatment. Researchers have isolated virus-neutralizing, fully human antibodies from lab mice, genetically-modified to have a human immune system, as well as humans who have recovered from COVID-19. Researchers will select the top two antibodies for a cocktail treatment, which the company says allows for targeting of different parts of the virus and may help protect against multiple viral variants.

FDA has approved the initiation of a phase 3 trial

 for the immunosuppressive drug tocilizumab (Actemra) to evaluate its safety and efficacy in combination with standard of care in hospitalized adult patients with severe COVID-19 pneumonia. Tocilizumab is an IL-6 receptor agonist approved for the treatment of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Finally, remdesivir (Gilead), an investigational monophosphoramidate prodrug of an adenosine analog that was developed in response to the 2014-2016 Ebola outbreak, is also being investigated. There are four clinical trials enrolling patients in the United States. The drug was available for compassionate use until

that access due to overwhelming demand. Gilead expects to set up a broader access program, but critically ill patients are now left in limbo.

The bottom line is that “we just don’t know what’s really going to pan out and what will be the most helpful right now,” says Dr. Ehrlich. “We just don’t have really strong clinical trial data yet. Until we have strong clinical trial data to support specific therapies for Covid-19 , it’s going to be  very challenging.”

Experts sent a letter to the White House Coronavirus Task Force March 24, outlining concerns about a growing shortage of medications required for managing patients with lupus and rheumatoid arthritis after President Donald Trump said in a March 19 press conference that the anti-malaria drug hydroxychloroquine could treat COVID-19.

Experts advise caution over early, emerging treatments

As the national pandemic continues to escalate, with new cases and findings about the COVID-19 virus coming daily, new insights are revealing the implications on dermatology practices and patients. To combat the pandemic, dermatologists must take critical steps to adapt operations while still providing essential patient care and preventing exposure in office settings, experts say.

, released March 19, George Hruza, M.D., president of the American Academy of Dermatology (AAD), shared the latest insight related to the dermatology specialty, which included guidance on self-protection, as well as the protection of staff and patients.

Among the resources provided were tips for patient screenings and effective disinfecting solutions for use around the clinic based on guidance from the Centers for Disease Control (CDC) and the World Health Organization (WHO). AAD is compiling all resources related to the pandemic for members, which can be found at 

According to the guidance, there are measures dermatologists can and should take 

. This includes, first, having a plan in place for any procedures to manage a patient who presents with signs or symptoms of COVID-19 infection. This plan should be clearly communicated to all staff members. The plan should also include protocol for informing patients of any changes to scheduling or policies that could take place due to the evolving nature of the outbreak. Importantly, any sick staff members should be encouraged to stay home.

Due to regulatory changes that were enacted to ease care delivery, physicians may be able to leverage telemedicine technology with patients exhibiting respiratory symptoms who also require dermatology care. Physicians can now receive reimbursement from Medicare, according to the AAD. The organization is working with private payers to develop similar service coverage. Updates, help with getting started and assistance with coding can be found through the 

Signs and symptoms of infection, according to CDC, include fever, cough, sore throat and shortness of breath. 

 a patient’s symptoms could indicate a COVID-19 infection, the patient should be immediately isolated, and proper steps should be taken to confirm infection and to notify the local or state health department.

 for healthcare facilities to manage infection risk in the workplace. Among recommendations, WHO suggests staff regularly wipe down all chairs and arm rests, exam room tables, counters, doorknobs, light buttons and handles, faucet handles, all bathroom surfaces, reception area counters, all lab surfaces, and all kitchen area surfaces; keep trash cans empty and wipe down the inside and outside of containers regularly and thoroughly.

AAD is developing further guidance for members on personnel issues and will provide updates as the information becomes available.

More information on managing infection risk, clinic operations and staffing can be found here:
	• AAD: 

Coronavirus Resources/Managing your practice through the COVID-19 outbreak

Interim Infection Prevention and Control Recommendations

The COVID-19 Risk Communication Package for Healthcare Facilities

As the national pandemic continues to escalate, the American Academy of Dermatology is actively compiling resources related to the novel coronavirus to support its members and their practices. 

AAD develops coronavirus resource center to support members through outbreak

Experts have advised that those at greatest risk if exposed to Covid-19 are those who are older, have underlying medical conditions or who are immunocompromised. This brings up the question of how to manage patients on immunomodulatory therapies for their dermatologic conditions. While there is no data on which to base guidelines, the American Academy of Dermatology (AAD) has issued interim recommendations for practitioners to balance the risk of immunosuppression with the risk of disease flare.

“A main priority for dermatologists, at this point, is to keep our patients out of emergency rooms and urgent care so as to not tax the healthcare system unnecessarily,” the statement, issued March 18, reads.

According to AAD’s current guidance, dermatologists are advised to keep patients on their biologic therapy if they have not tested positive or do not exhibit signs or symptoms of COVID-19. According to AAD, there is currently insufficient data to recommend discontinuing therapy. However, physicians are advised to actively discuss the risks and benefits with their patients, weighing the severity of the patient’s indication for therapy, the patient’s age and any comorbidity concerns that would place the patient at high risk for serious illness should they be exposed to the virus.

If a patient has tested positive for COVID-19, physicians should follow the guidelines for managing patients on biologics with active infections, and discontinue or postpone the start of therapy until the patient recovers, AAD recommends.

If a patient is a candidate for biologic therapy, AAD recommends that physicians assess the individual risk vs. benefit profile of treatment in patients at low-risk for serious illness from COVID-19. If a patient is in a high-risk population, it may be more prudent to utilize alternative therapeutic approaches and delay biologic initiation at this time.

For more information, AAD is setting up a page dedicated to the impact of COVID-19 in the dermatology specialty. You can find 

The American Academy of Dermatology (AAD) has issued interim recommendations for practitioners to balance the risk of immunosuppression with the risk of disease flare amid COVID-19 pandemic.

AAD issues guidance on biologic therapy during COVID-19 pandemic

In their novel presentation on new drugs and therapies in 2020 at the current Maui Derm for Dermatologists, Ted Rosen, M.D., Houston, Texas and Neal Bhatia, M.D., San Diego, Cali., tackled the up-and-coming treatments hitting the industry.

Dressed as Carnac the Magnificent from the Johnny Carson show, Dr. Bhatia took the stage with Dr. Rosen to answer questions and inform the audience, all while in character.

“[It’s] different than usual medical meeting talk, that's for darn sure,” says Dr. Rosen.

Talking about acne in 2020, Dr. Rosen says it “has been a banner year for new drugs.”

Trifarotene, the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, has shown promising results, he says.

“We have a brand-new molecule, a new retinoid trifarotene in a cream, which not only studied facial acne but deliberately studied and showed good results in truncal acne,” he says.

Clascoterone, the first and only anti-androgen as a topical, was also highlighted in the presentation.

“It has to be used couple times a day, but it looks very, very promising, and it's different from all our other agents,” he says. “It's a competitive inhibitor of DHT for those androgen receptors.”

The last acne topical that was discussed, minocycline 4%, which Dr. Rosen says is interesting because of its formulation.

“This is going to be in a foam formulation, and you know people like foam,” he says.

Though it has been attempted in years past to make minocycline into a topical, he says that it’s only recently been possible due to new technology.

“This is a new technology with ultra-micronized minocycline,” he says. “It's only about three microns so it can easily get into the follicles which are about 60 microns more or less across.”

Interestingly, he notes that a lot of the new drugs are actually old drugs with new technologies.

Two of those drugs, betamethasone dipropionate, along with calcipotriene but it's in a new formulation, use PAD technology, “where the oil droplets are in a honeycomb matrix, which melts when it hits the skin.”

When tested in a head-to-head study, the drugs using pad technology beat the same ingredients in a suspension form.

For molluscum contagiosum, Dr. Rosen expressed his interest in a new 0.7% cantharidin product that has recently been FDA approved.

“It's in a precise applicator with a dye so you know which lesions you've treated, and which you haven't,” he says. “It's done once every 21 days, up to a maximum of four times and lesion clearance was quite good. Sixty-three percent to 83% of lesions in general disappeared. But even better if you looked at important sites like the head and neck, the face, the groin, the genitalia, you had over 80% completely clear by day 84.”

Highlighting one self-professed ‘oddball new drug,’ Dr. Rosen touched on the IV formulation of cetirizine for the treatment of acute urticaria.

“It’s a single dose every 24 hours and approved all the way down to six months of age,” he says. “Mostly it'll be used for adults and adolescence, but clearly a major advance in the treatment of bad urticaria because there are very few people have returned for any additional treatment.”

In a skit depicting Carnac the Magnificent, Drs. Rosen and Bhatia presented on 2020's new drugs and technologies at the current Maui Derm for Dermatologists, all with a magical twist.

Latest Conference Articles